

Fernando Bril

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/272844/fernando-bril-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

72
papers

3,513
citations

29
h-index

59
g-index

79
ext. papers

4,628
ext. citations

5.9
avg, IF

5.87
L-index

#	Paper	IF	Citations
72	Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver. <i>Current Hypertension Reviews</i> , 2021 , 17, 94-111	2.3	3
71	Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. <i>Diabetes Care</i> , 2021 , 44, 399-406	14.6	39
70	Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e4360-e4371	5.6	1
69	Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes. <i>PLoS ONE</i> , 2021 , 16, e0251449	3.7	2
68	Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?. <i>Journal of Hepatology</i> , 2021 , 75, 222-224	13.4	52
67	PPAR- γ -Induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH. <i>Liver International</i> , 2021 , 41, 2659-2670	7.9	13
66	Autoimmunity after Coronavirus Disease 2019 (COVID-19) Vaccine: A Case of Acquired Hemophilia A. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 1674-1676	7	10
65	Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: One or even several swallows do not make a summer. <i>Journal of Hepatology</i> , 2021 , 75, 1256-1257	13.4	7
64	What the New Definition of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Left Behind: Genetically Acquired Fatty Liver Disease (GAFLD). <i>EBioMedicine</i> , 2021 , 72, 103584	8.8	0
63	Reply to: "Comment on "Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?". <i>Journal of Hepatology</i> , 2021 , 75, 996-997	13.4	0
62	Targeting pheochromocytoma/paraganglioma with polyamine inhibitors. <i>Metabolism: Clinical and Experimental</i> , 2020 , 110, 154297	12.7	3
61	MON-199 Targeting Pheochromocytoma/Paraganglioma with Polyamine Inhibitors. <i>Journal of the Endocrine Society</i> , 2020 , 4,	0.4	78
60	1461-P: Liver Fibrosis Is Common in Patients with Type 2 Diabetes Mellitus (T2DM) and Nonalcoholic Fatty Liver Disease (NAFLD). <i>Diabetes</i> , 2020 , 69, 1461-P	0.9	1
59	MON-644 Prevalence of Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Patients with Type 2 Diabetes Mellitus. <i>Journal of the Endocrine Society</i> , 2020 , 4,	0.4	78
58	1463-P: Relationship between Hepatic and Adipose Tissue Insulin Resistance with Liver Fibrosis in Patients with Type 2 Diabetes Mellitus (T2DM) and Nonalcoholic Fatty Liver Disease (NAFLD). <i>Diabetes</i> , 2020 , 69, 1463-P	0.9	
57	Central Nervous System Depressants and Risk of Hospitalization due to Community-Acquired Pneumonia in very Old Patients. <i>Current Drug Safety</i> , 2020 , 15, 131-136	1.4	0
56	Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2020 , 43, 290-297	14.6	61

55	Relationship between non-alcoholic fatty liver disease during pregnancy and abnormal glucose metabolism during and after pregnancy. <i>Journal of Investigative Medicine</i> , 2020 , 68, 743-747	2.9	5
54	Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis. <i>Journal of Hepatology</i> , 2020 , 72, 401-410	13.4	21
53	Letter to the Editor: "Hepatic Insulin Extraction in NAFLD Is Related to Insulin Resistance Rather Than Liver Fat Content". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 5249-5250	5.6	
52	Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial. <i>Diabetes Care</i> , 2019 , 42, 1481-1488	14.6	105
51	Emerging Circulating Biomarkers for The Diagnosis and Assessment of Treatment Responses in Patients with Hepatic Fat Accumulation, Nash and Liver Fibrosis 2019 , 423-448		4
50	Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 3327-3336	5.6	33
49	Drug Development for Diabetes Mellitus: Beyond Hemoglobin A1c 2019 , 405-421		
48	Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36-month clinical trial. <i>Journal of Diabetes</i> , 2019 , 11, 223-231	3.8	16
47	Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes. <i>Diabetes Care</i> , 2019 , 42, 1348-1351	14.6	19
46	Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis. <i>Journal of Endocrinology</i> , 2019 , 241, 293-305	4.7	15
45	223-OR: Pioglitazone Discontinuation in Patients with Nonalcoholic Steatohepatitis (NASH) Is Associated with Disease Recurrence. <i>Diabetes</i> , 2019 , 68, 223-OR	0.9	2
44	Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2019 , 70, 711-724	11.2	112
43	Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 812-821	6.7	65
42	Re: "Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis" by Mantovani et al. (<i>Thyroid</i> 2018;28:1270-1284). <i>Thyroid</i> , 2019 , 29, 452	6.2	3
41	Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus. <i>Journal of Investigative Medicine</i> , 2019 , 67, 303-311	2.9	34
40	Basic Concepts in Insulin Resistance and Diabetes Treatment 2018 , 19-35		3
39	Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 558-566.e2	6.9	103
38	Use of a metabolomic approach to non-invasively diagnose non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1702-1709	6.7	24

37	Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2018 , 315, E163-E173	6	34
36	A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis. <i>Frontiers in Pharmacology</i> , 2018 , 9, 752	5.6	14
35	Role of Vitamin E for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients with T2DM: A Randomized, Controlled Trial. <i>Diabetes</i> , 2018 , 67, 1223-P	0.9	1
34	Use of Plasma Metabolomics and Lipidomics for the Diagnosis of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes. <i>Diabetes</i> , 2018 , 67, 1847-P	0.9	
33	Exenatide Treatment Improves Mitochondrial Metabolism and Hepatic Insulin Sensitivity in Mice with Nonalcoholic Steatohepatitis (NASH). <i>Diabetes</i> , 2018 , 67, 1846-P	0.9	
32	Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients. <i>Diabetes Care</i> , 2018 , 41, 187-192	14.6	23
31	Response to Comment on Brill et al. Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients. <i>Diabetes Care</i> 2018;41:187-192. <i>Diabetes Care</i> , 2018 , 41, e137-e138	14.6	2
30	Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. <i>Diabetes Care</i> , 2017 , 40, 419-430	14.6	172
29	Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis. <i>Annals of Internal Medicine</i> , 2017 , 166, 230	8	4
28	Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 56-61	6.1	13
27	Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 2950-2961	5.6	44
26	Liver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culprit. <i>Hepatology</i> , 2017 , 66, 296-297	11.2	5
25	Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2017 , 65, 1132-1144	11.2	134
24	Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies. <i>Trends in Endocrinology and Metabolism</i> , 2017 , 28, 250-260	8.8	155
23	Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2016 , 39, 632-8	14.6	76
22	Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 644-52	5.6	95
21	A Systematic Approach to Assess the Burden of Drug Interactions in Adult Kidney Transplant Patients. <i>Current Drug Safety</i> , 2016 , 11, 156-63	1.4	12
20	Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. <i>Annals of Internal Medicine</i> , 2016 , 165, 305-15	8	494

19	Plasma thyroid hormone concentration is associated with hepatic triglyceride content in patients with type 2 diabetes. <i>Journal of Investigative Medicine</i> , 2016 , 64, 63-8	2.9	16
18	Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus. <i>Endocrinology and Metabolism Clinics of North America</i> , 2016 , 45, 765-781	5.5	79
17	Treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) 2015 , 292-305		1
16	The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2015 , 61, 153-60	11.2	116
15	Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients. <i>Liver International</i> , 2015 , 35, 2139-46	7.9	104
14	Response to do ultrasonographic semiquantitative indices predict histological changes in NASH irrespective of steatosis extent?. <i>Liver International</i> , 2015 , 35, 2341-2	7.9	1
13	High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 2231-8	5.6	304
12	Cross-talk between branched-chain amino acids and hepatic mitochondria is compromised in nonalcoholic fatty liver disease. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2015 , 309, E311-9	6	63
11	Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2015 , 62, 405-11	13.4	85
10	Role of Insulin Resistance and Diabetes in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease. <i>Current Hepatology Reports</i> , 2014 , 13, 159-170	1	16
9	Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2014 , 59, 2178-87	11.2	89
8	Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2014 , 60, 167-74	13.4	184
7	A validated liquid chromatography tandem mass spectrometry method for simultaneous determination of pioglitazone, hydroxypioglitazone, and ketopioglitazone in human plasma and its application to a clinical study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014 , 969, 219-23	3.2	10
6	High Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 100,	5.6	13
5	Nonalcoholic fatty liver disease: current issues and novel treatment approaches. <i>Drugs</i> , 2013 , 73, 1-14	12.1	123
4	Adverse drug reactions as a reason for admission to an internal medicine ward in Argentina. <i>International Journal of Risk and Safety in Medicine</i> , 2013 , 25, 185-92	1.6	14
3	The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease. <i>Clinical Lipidology</i> , 2012 , 7, 471-481		15
2	Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2011 , 54, 837-45	11.2	63

1 Antimicrobial agents-associated with QT interval prolongation. *Current Drug Safety*, **2010**, 5, 85-92 1.4 23